Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma

Journal of Clinical Oncology

Volumn 28, Issue 11, 2010, Pages 1870-1877

  Prince, H Miles ^a   Duvic, Madeleine ^a   Martin, Ann ^a   Sterry, Wolfram ^a   Assaf, Chalid ^a   Sun, Yijun ^a   Straus, David ^a   Acosta, Mark ^a   Negro Vilar, Andres ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFTITOX; PLACEBO; ANTINEOPLASTIC AGENT; DIPHTHERIA TOXIN; HYBRID PROTEIN; INTERLEUKIN 2;

ABDOMINAL PAIN; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER STAGING; CAPILLARY LEAK SYNDROME; CD25+ T LYMPHOCYTE; CUTANEOUS T CELL LYMPHOMA; DEHYDRATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLUSHING; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SEZARY SYNDROME; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; INTERNATIONAL COOPERATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SAFETY; SKIN TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-2; INTERNATIONAL AGENCIES; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLACEBOS; RECOMBINANT FUSION PROTEINS; SAFETY; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951650540     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.2386     Document Type: Article

References (32)

1. Hoppe RT, Wood GS, Abel EA: Mycosis fungoides and the Sézary syndrome: Pathology, staging, and treatment. Curr Probl Cancer 14:293-371, 1990
2. Wood GS, Weiss LM, Warnke RA, et al: The immunopathology of cutaneous lymphomas: Immunophenotypic and immunogenotypic characteristics. Semin Dermatol 5:334-345, 1986 (Pubitemid 17038748)
3. Willemze R, Jaffe ES, Burg G, et al: WHOEORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
4. Quereux G, Marques S, Nguyen J-M, et al: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144:727-733, 2008 (Pubitemid 351846873)
5. Akpek G, Koh HK, Bogen S, et al: Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 86:1368-1376, 1999 (Pubitemid 29447025)
6. Crovetti G, Carabelli A, Berti E, et al: Photopheresis in cutaneous T-cell lymphoma: Five-year experience. Int J Artif Organs 23:55-62, 2000 (Pubitemid 30116416)
7. Stadler R, Otte H-G, Luger T, et al: Prospective randomized multicenter clinical trial on the use of interferon a-2A plus acitretin versus interferon a-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 92:3578-3581, 1998 (Pubitemid 28525182)
8. Duvic M, Hymes K, Heald P, et al: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 19:2456-2471, 2001 (Pubitemid 32391217)
9. Merck: Zolinza (vorinostat) prescribing information. Whitehouse Station, NJ, Merck, 2008
10. Prince HM, Bishton MJ, Harrison SJ: Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958-3969, 2009
11. Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 85:1985-1995, 1999
12. Kim YH, Chow S, Varghese A, et al: Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 135:26-32, 1999 (Pubitemid 29069513)
13. Kim YH, Martinez G, Varghese A, et al: Topical nitrogen mustard in the management of mycosis fungoides: Update of the Stanford experience. Arch Dermatol 139:165-173, 2003 (Pubitemid 36216254)
14. Kim YH, Liu HL, Mraz-Gernhard S, et al: Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol 139:857-866, 2003 (Pubitemid 36898920)
15. Mostow EN, Neckel SL, Oberhelman L, et al: Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 129:747-752, 1993 (Pubitemid 23172779)
16. Rupoli S, Goteri G, Pulini S, et al: Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 75:136-145, 2005 (Pubitemid 41008284)
17. Wilson LD, Kaginski BM, Edelson RL, et al: Cutaneous T-cell lymphomas, in Devita VT, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology (ed 5). New York, NY, Lippincott-Raven, 1997, pp 2220-2232
18. Wollina U, Liebold K, Kaatz M, et al: Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy. Oncol Rep 7:1197-1201, 2000
19. Wollina U, Dummer R, Brockmeyer NH, et al: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993-1001, 2003 (Pubitemid 37022100)
20. Zackheim HS, Amin S, Kashani-Sabet M, et al: Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. J Am Acad Dermatol 40:418-425, 1999 (Pubitemid 29115302)
21. Taniguchi T, Minami Y: The IL-2/IL-2 receptor system: A current overview. Cell 73:5-8, 1993 (Pubitemid 23115443)
22. Nakase K, Kita K, Nasu K, et al: Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 46:179-183, 1994 (Pubitemid 24206741)
23. Nichols J, Foss F, Kuzel TM, et al: Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 33:S34-S36, 1997 (suppl 1)
24. Re GG, Waters C, Poisson L, et al: Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res 56:2590-2595, 1996
25. Waters CA, Schimke PA, Snider CE, et al: Interleukin 2 receptor-targeted cytotoxicity: Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur J Immunol 20:785-791, 1990 (Pubitemid 20167033)
26. Olsen E, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388, 2001 (Pubitemid 32112849)
27. Negro-Vilar A, Prince HM, Duvic M, et al: Efficacy and safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three large phase III trials. J Clin Oncol 26:466s, 2008 (suppl; abstr 8551)
28. Bunn PA Jr, Lamberg SI: Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 63:725-728, 1979
29. Stevens SR, Ke MS, Mark J, et al: Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: The Severity-Weighted Assessment Tool (SWAT). Arch Dermatol 138:42-48, 2002 (Pubitemid 34056233)
30. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research: FDA guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/OHRMS/DOCKETS/98fr/ E7-9345.pdf
31. Spruance SL, Reid JE, Grace M, et al: Hazard ratio in clinical trials. Antimicrob Agents Chemother 48:2787-2792, 2004 (Pubitemid 38989137)
32. Stokes ME, Davis CS, Koch GG: Categorical Data Analysis Using the SAS System (ed 2). Cary, NC, SAS Institute, 2000